



ASHMET, CO2 A1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	See Exhibit "A")
)
App. No.	:	See Exhibit "A")
)
Filed	:	See Exhibit "A")
)
For	:	See Exhibit "A")
)

REVOCATION OF POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The undersigned hereby revokes any previous powers of attorney in the subject application, namely that of Knobbe, Martens, Olson & Bear, LLP, Customer No. 20,995, including all of the individual members of the firm, 2040 Main Street, Fourteenth Floor, Irvine, California 92614, and requests that all future communications with respect thereto from the Patent and Trademark Office be forwarded to:

Cathryn Campbell, Esq.
McDermott, Will & Emery
4370 La Jolla Village Drive, 7th Floor
San Diego, CA 92122
Bus: 858/ 535-9001
Bus Fax: 858/ 597-1585

METAGENICS, INC.

Dated: August 7, 2003

By: Susan Y. Campbell
Title: General Counsel

EXHIBIT "A"
TO REVOCATION OF POWER OF ATTORNEY

APPLICANT(S)	SERIAL NO.	FILED	TITLE	ATTY. CODE
Babish, J., et al	09/885,721	6/20/01	Complex Mixtures Exhibiting Selective Inhibition of Cyclooxygenase-2	ASHMET.001A
Babish, J., et al	10/280,198	10/24/02	Complex Mixtures Exhibiting Selective Inhibition of Cyclooxygenase-2	ASHMET.001DV1
Babish, J., et al	09/919,349	7/31/01	Combinations of Sesquiterpene Lactones and Diterpene Triepoxide Lactones for Synergistic Inhibition	ASHMET.002A1
Babish, J., et al	09/919,506	7/31/01	Combinations of Sesquiterpene Lactones and Diterpene Triepoxide Lactones for Synergistic Inhibition	ASHMET.002A2
Babish, J., et al	09/920,339	8/1/01	Combinations of Diterpene Triepoxide Lactones and Diterpene Lactones or Triterpenes for	ASHMET.004A
Babish, J., et al	10/198,277	7/16/02	Curcuminoid Compositions Exhibiting Synergistic Inhibition of the Expression and/or Activity of....	ASHMET.005A
Babish, J.	10/234,002	8/29/02	Arginine Compositions For Coordinate Modification of Multiple Cardiovascular Risk	ASHMET.006A
Babish, J., et al	10/282,236	10/25/02	Curcuminoid Compositions Exhibiting Synergistic Inhibition of The Expression and/or Activity of...	ASHMET.007A
Pacioretty, L, et al.	10/163,254	6/4/02	Oral Composition With Insulin-Like Activities and Methods of Use	ASHMET.008A
Tripp, M., et al.	10/400,293	3/26/03	Modulation of NF-KB By Hops Fractions and Derivatives	ASHMET.017A
Tripp, M., et al.	10/401,283	3/26/03	Synergistic Compositions that Treat or Inhibit Pathological Conditions Associated with.....	ASHMET.017A2
Tripp, M., et al.	10/464,834	6/18/03	Modulation of Inflammation by Hops Fractions and Derivatives	ASHMET.017CP1
Tripp, M., et al.	10/464,410	6/18/03	Synergistic Compositions that Treat or Inhibit Pathological Conditions Associated with....	ASHMET.017CP2

CCT-4912.DOC:cb 080103